Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

19.2%

14 terminated/withdrawn out of 73 trials

Success Rate

79.1%

-7.4% vs industry average

Late-Stage Pipeline

19%

14 trials in Phase 3/4

Results Transparency

51%

27 of 53 completed trials have results

Key Signals

27 with results9 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 1

32(45.1%)

Phase 2

25(35.2%)

Phase 3

13(18.3%)

Phase 4

1(1.4%)

71Total

Phase 1(32)

Phase 2(25)

Phase 3(13)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (73)

Showing 20 of 73 trials

NCT03246347Phase 2Active Not Recruiting

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Role: collaborator

NCT02023463Phase 1Active Not Recruiting

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Role: collaborator

NCT02203695Phase 2Completed

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Role: collaborator

NCT02007512Phase 2Completed

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Role: collaborator

NCT01990196Phase 2Active Not Recruiting

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Role: collaborator

NCT02750358Phase 2Active Not Recruiting

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Role: collaborator

NCT02339168Phase 1Completed

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

Role: collaborator

NCT01096602Phase 2Completed

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

Role: collaborator

NCT02495974Completed

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Role: collaborator

NCT03148795Phase 2Completed

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Role: collaborator

NCT01949337Phase 3Unknown

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Role: collaborator

NCT02028988Phase 2Completed

Enzalutamide + External Beam Rt For Prostate

Role: collaborator

NCT01974765Phase 2Completed

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Role: collaborator

NCT01942837Phase 2Completed

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Role: collaborator

NCT02049593Phase 1Completed

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Role: collaborator

NCT02921919Phase 2Completed

Open-Label Extension and Safety Study of Talazoparib

Role: collaborator

NCT02268175Phase 2Completed

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Role: collaborator

NCT01945775Phase 3Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Role: collaborator

NCT02127151Phase 2Withdrawn

A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer

Role: collaborator

NCT03077607Phase 1Completed

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Role: collaborator